Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma

Kota Ramana, U. C S Yadav, William Calhoun, Satish Srivastava

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The prevalence of asthma and costs of its care have been continuously increasing, but novel therapeutic options to treat this inflammatory disease have not been brought to the US market. Current therapies such as inhaled steroids, long-acting beta-agonist bronchodilators, antihistamines and immunomodulators may control the symptoms of allergic asthma but fail to modify the underlying disease. Excessive use of steroids and other immunosuppresents alter the patient's quality of life, produce undesirable toxicities, and increase the risk of other pathologies such as diabetes. Hence novel therapeutic options to manage asthma are desirable. In the present review, we have discussed the role of the polyol pathway enzyme aldose reductase (AR) in the amplification of allergic airway inflammation. Recent studies have indicated that AR inhibition prevents the NF-kB-dependent generation of pro-inflammatory cytokines and chemokines in mouse models of allergic airway inflammation indicating the potential use of AR inhibition as a novel tool to control allergic responses. Since orally available AR inhibitors have already undergone phase III clinical trials for diabetic neuropathy and appear to have a manageable side effects profile, they could be readily developed as potential new drugs for the treatment of asthma and related complications.

Original languageEnglish (US)
Pages (from-to)599-608
Number of pages10
JournalCurrent Molecular Medicine
Volume11
Issue number7
StatePublished - 2011

Fingerprint

Aldehyde Reductase
Asthma
Inflammation
Steroids
Phase III Clinical Trials
Diabetic Neuropathies
NF-kappa B
Histamine Antagonists
Bronchodilator Agents
Immunologic Factors
Pathology
Therapeutics
Medical problems
Chemokines
Amplification
Toxicity
Quality of Life
Cytokines
Costs and Cost Analysis
Enzymes

Keywords

  • Airway inflammation
  • Aldose reductase
  • Asthma
  • Polyol pathway

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma. / Ramana, Kota; Yadav, U. C S; Calhoun, William; Srivastava, Satish.

In: Current Molecular Medicine, Vol. 11, No. 7, 2011, p. 599-608.

Research output: Contribution to journalArticle

@article{5ed817b9eb8d4817bfa78e4c89b26314,
title = "Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma",
abstract = "The prevalence of asthma and costs of its care have been continuously increasing, but novel therapeutic options to treat this inflammatory disease have not been brought to the US market. Current therapies such as inhaled steroids, long-acting beta-agonist bronchodilators, antihistamines and immunomodulators may control the symptoms of allergic asthma but fail to modify the underlying disease. Excessive use of steroids and other immunosuppresents alter the patient's quality of life, produce undesirable toxicities, and increase the risk of other pathologies such as diabetes. Hence novel therapeutic options to manage asthma are desirable. In the present review, we have discussed the role of the polyol pathway enzyme aldose reductase (AR) in the amplification of allergic airway inflammation. Recent studies have indicated that AR inhibition prevents the NF-kB-dependent generation of pro-inflammatory cytokines and chemokines in mouse models of allergic airway inflammation indicating the potential use of AR inhibition as a novel tool to control allergic responses. Since orally available AR inhibitors have already undergone phase III clinical trials for diabetic neuropathy and appear to have a manageable side effects profile, they could be readily developed as potential new drugs for the treatment of asthma and related complications.",
keywords = "Airway inflammation, Aldose reductase, Asthma, Polyol pathway",
author = "Kota Ramana and Yadav, {U. C S} and William Calhoun and Satish Srivastava",
year = "2011",
language = "English (US)",
volume = "11",
pages = "599--608",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - Current prospective of aldose reductase inhibition in the therapy of allergic airway inflammation in asthma

AU - Ramana, Kota

AU - Yadav, U. C S

AU - Calhoun, William

AU - Srivastava, Satish

PY - 2011

Y1 - 2011

N2 - The prevalence of asthma and costs of its care have been continuously increasing, but novel therapeutic options to treat this inflammatory disease have not been brought to the US market. Current therapies such as inhaled steroids, long-acting beta-agonist bronchodilators, antihistamines and immunomodulators may control the symptoms of allergic asthma but fail to modify the underlying disease. Excessive use of steroids and other immunosuppresents alter the patient's quality of life, produce undesirable toxicities, and increase the risk of other pathologies such as diabetes. Hence novel therapeutic options to manage asthma are desirable. In the present review, we have discussed the role of the polyol pathway enzyme aldose reductase (AR) in the amplification of allergic airway inflammation. Recent studies have indicated that AR inhibition prevents the NF-kB-dependent generation of pro-inflammatory cytokines and chemokines in mouse models of allergic airway inflammation indicating the potential use of AR inhibition as a novel tool to control allergic responses. Since orally available AR inhibitors have already undergone phase III clinical trials for diabetic neuropathy and appear to have a manageable side effects profile, they could be readily developed as potential new drugs for the treatment of asthma and related complications.

AB - The prevalence of asthma and costs of its care have been continuously increasing, but novel therapeutic options to treat this inflammatory disease have not been brought to the US market. Current therapies such as inhaled steroids, long-acting beta-agonist bronchodilators, antihistamines and immunomodulators may control the symptoms of allergic asthma but fail to modify the underlying disease. Excessive use of steroids and other immunosuppresents alter the patient's quality of life, produce undesirable toxicities, and increase the risk of other pathologies such as diabetes. Hence novel therapeutic options to manage asthma are desirable. In the present review, we have discussed the role of the polyol pathway enzyme aldose reductase (AR) in the amplification of allergic airway inflammation. Recent studies have indicated that AR inhibition prevents the NF-kB-dependent generation of pro-inflammatory cytokines and chemokines in mouse models of allergic airway inflammation indicating the potential use of AR inhibition as a novel tool to control allergic responses. Since orally available AR inhibitors have already undergone phase III clinical trials for diabetic neuropathy and appear to have a manageable side effects profile, they could be readily developed as potential new drugs for the treatment of asthma and related complications.

KW - Airway inflammation

KW - Aldose reductase

KW - Asthma

KW - Polyol pathway

UR - http://www.scopus.com/inward/record.url?scp=80053980973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053980973&partnerID=8YFLogxK

M3 - Article

C2 - 21707512

AN - SCOPUS:80053980973

VL - 11

SP - 599

EP - 608

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 7

ER -